AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Photocure ASA

Report Publication Announcement Aug 4, 2021

3714_rns_2021-08-04_534b8fc5-8b66-4198-b5f6-b20fc2aad845.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Photocure ASA: Invitation to presentation of second quarter and first half year 2021 financial results

Oslo, Norway, 4 August 2021: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2021 financial results on Wednesday 11 August 2021 at 07:30 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

The investor presentation will be streamed live and be hosted by Daniel Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event.

The quarterly report and presentation will be published at 07:00 CET and will be publicly available at www.photocure.com. The streaming event is available through https://channel.royalcast.com/landingpage/hegnarmedia/20210811\_2/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Photocure

Erik Dahl CFO Tel: +47 45055000 Email: [email protected]

Media and IR enquiries: Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: [email protected]

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.